Cassava Sciences Stock Crashes After Alzheimer’s Drug Fails
Haider Shah Cassava Sciences (NASDAQ: SAVA) plummeted over 83% on Monday following a report that its Alzheimer’s treatment, similar, did not meet the main objectives in Phase 3 trials. The study, known…